{"database": "press", "table": "releases", "rows": [["https://www.murphy.senate.gov/newsroom/press-releases/murphy-highlights-sheltons-aspira-womens-health-as-innovator-of-the-month", "Murphy Highlights Shelton's Aspira Women's Health As \"Innovator Of The Month\"", "2024-11-04", "2024", "2024-11", "Democrat", "Senate", "CT", "Christopher Murphy", "M001169", "www.murphy.senate.gov", "chrismurphy", "https://www.murphy.senate.gov/newsroom/press-releases", "scraper", "HARTFORD\u2013U.S. Senator Chris Murphy (D-Conn.) announced on Monday that Aspira Women\u2019s Health, a bio-analytical company based in Shelton, was named \u201cInnovator of the Month\u201d for its leadership in the development of blood tests that aid in the detection of ovarian cancer. The company\u2019s flagship products, OvaWatch and Ova1Plus, employ AI technology towards effective ovarian cancer risk assessment and drive higher standard of care for women with ovarian masses. Last month, Aspira was awarded $10 million in federal funding to develop a non-invasive blood test to detect endometriosis, which is currently diagnosed through invasive surgery.\n\n\u201cFor decades, underinvestment in women\u2019s health has meant that women and girls simply aren\u2019t getting access to the treatments and care they deserve. I\u2019m proud to see Aspira\u2019s cutting-edge biomedical research positioning Connecticut as a leader in women\u2019s healthcare and improving lives through earlier risk assessment, more accurate diagnoses, and innovative, personalized care,\u201d said Murphy.\n\n\u201cWe are honored to be Innovator of the Month and proud to represent Connecticut on the national women\u2019s healthcare stage. For far too long, women have been forced to resort to surgical interventions for diagnosis of gynecologic diseases. Aspira aims to change that. We believe all women deserve the opportunity to make healthcare decisions based on facts instead of fear,\u201d said Nicole Sandford, CEO of Aspira Women\u2019s Health. \u201cEndometriosis is a chronic condition that impacts as many as six million women in the United States alone. It alters nearly every facet of a patient\u2019s life, many of whom must wait years for a diagnosis. We believe Aspira is uniquely qualified to solve this problem. Our diagnostic solutions focus on a data-driven approach and powerful AI-enabled algorithms that offer noninvasive alternatives to aid in the detection of gynecologic disease. Our suite of blood tests to assess ovarian cancer risk in women with masses which have been ordered by healthcare providers more than 200,000 times. We believe this experience and experience is critical for the development of a noninvasive endometriosis test.\u201d\n\nAspira Women\u2019s Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases. OvaWatch\u00ae and Ova1Plus\u00ae are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer risk for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of 99% and is used to assess ovarian cancer risk for women where initial clinical assessment indicates the mass is indeterminate or benign, and thus surgery may be premature or unnecessary. Ova1Plus is a reflex process of two FDA-cleared tests, Ova1\u00ae and Overa\u00ae, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery.\n\nMurphy believes entrepreneurship and innovation are the building blocks for a strong economy. In the U.S. Senate, he has introduced legislation to incentivize angel investors to put more money into startup companies\u2014the Angel Tax Credit Act and the Helping Angels Lead Our Startups (HALOS) Act. Startup companies create an average of 2 million jobs each year.\n\n###", 1, "2026-03-30T01:40:41Z", "2026-04-07T22:07:06Z"]], "columns": ["url", "title", "date", "year", "month", "party", "chamber", "state", "member_name", "bioguide_id", "domain", "scraper", "source", "date_source", "text", "has_text", "collected_at", "updated_at"], "primary_keys": ["url"], "primary_key_values": ["https://www.murphy.senate.gov/newsroom/press-releases/murphy-highlights-sheltons-aspira-womens-health-as-innovator-of-the-month"], "units": {}, "query_ms": 1.542300044093281, "source": "dwillis/congress-press", "source_url": "https://github.com/dwillis/congress-press", "license": "MIT", "license_url": "https://github.com/dwillis/congress-press/blob/main/LICENSE"}